Latest Content

This timeline highlights 5 key dates in September when the FDA approved treatments for cancers, dermatologic conditions, and rare diseases.

Discover how the SkinTracker app enhances AD management through remote assessments, offering convenience and accuracy comparable to in-person visits.

Questions remain related to which patients with diffuse large B-cell lymphoma (DLBCL) benefit most from radiotherapy and at what dose.

The FDA has approved belantamab mafodotin for third-line or later multiple myeloma based on DREAMM-7 trial data.

Removing out-of-pocket costs for follow-up colonoscopy led to an immediate and sustained increase in utilization.

Heart rate variability (HRV) biofeedback may be a potential intervention for patients with coronary artery disease.

Which hormonal contraceptives are still safe, when should women stop using them, and what other benefits do they offer during the menopause transition?

Explore the critical implications of proposed Medicaid cuts on health care access, costs, and community well-being in the US.

Different cultural, linguistic, and systemic barriers could impact how Indigenous and Hispanic women access menopause care, said Lisa Taylor-Swanson, PhD.